Cargando…
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade
BACKGROUND: New molecular targets are needed for women with triple-negative breast cancer (TNBC). This pre-clinical study investigated the combination of the EGFR inhibitor gefitinib with the sphingosine kinase (SphK) inhibitor FTY720 (Fingolimod), aiming to block tumorigenic signaling downstream of...
Autores principales: | Martin, Janet L., Julovi, Sohel M., Lin, Mike Z., de Silva, Hasanthi C., Boyle, Frances M., Baxter, Robert C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545026/ https://www.ncbi.nlm.nih.gov/pubmed/28778177 http://dx.doi.org/10.1186/s13058-017-0882-x |
Ejemplares similares
-
FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017) -
FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
por: Chung, Wei-Pang, et al.
Publicado: (2022) -
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017) -
FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015) -
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model
por: Szymiczek, Agata, et al.
Publicado: (2017)